Glenmark Pharmaceuticals has informed about a Press Release dated July 27, 2016 titled ‘Glenmark Pharmaceuticals receives ANDA approval for Potassium Chloride Extended-Release Tablets USP, 10 mEq (750 mg) and 20 mEq (1500 mg)’.
The above information is a part of company’s filings submitted to BSE.